Unique ID issued by UMIN | UMIN000000952 |
---|---|
Receipt number | R000001133 |
Scientific Title | A preventive effect of pancreatic duct stenting to decrease the rate of pancreatic fistula after pancreaticojejunostomy following pancreatoduodenectomy |
Date of disclosure of the study information | 2007/12/20 |
Last modified on | 2013/08/01 18:28:37 |
A preventive effect of pancreatic duct stenting to decrease the rate of pancreatic fistula after pancreaticojejunostomy following pancreatoduodenectomy
A preventive effect of pancreatic duct stenting to decrease the rate of pancreatic fistula after pancreaticojejunostomy
A preventive effect of pancreatic duct stenting to decrease the rate of pancreatic fistula after pancreaticojejunostomy following pancreatoduodenectomy
A preventive effect of pancreatic duct stenting to decrease the rate of pancreatic fistula after pancreaticojejunostomy
Japan |
pancreatoduodenectomy for pancreatic head cancer, bile duct cancer, cancer of the Vater's papilla, gallbladder cancer, pancreatic head tumor (Intraductal papillary-mucinous neoplasm, endocrine tumor, other pancreatic tumor), chronic pancreatitis
Hepato-biliary-pancreatic surgery |
Malignancy
NO
To invstigate the preventive effect of pancreatic duct stenting to decrease the pancreatic fistula after pancreaticojejunostomy following pancreatoduodenectomy
Safety,Efficacy
Confirmatory
Explanatory
Phase II,III
Rate and severity of pancreatic fistula
postoperative morbidity rate, postoperative hospital stay, hospital mortality rate
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
YES
NO
Institution is considered as a block.
YES
Numbered container method
2
Treatment
Maneuver |
Stented group
Nonstented group
18 | years-old | <= |
Not applicable |
Male and Female
1)all adult patient who are anticipate to undergo pancreatoduodenectomy
2)reconstruction feasible for pancreaticojejunostomy
3) written informed consent
1)requiring total pancreatectomy
2)unfeasible for pancreaticojejunostomy
3)past history for pancreatectomy
4)other unfeasible factors to study safety, approved attending surgeon
5)pregnancy
60
1st name | |
Middle name | |
Last name | Unno Michiaki |
Tohoku University Hospital
Hepato-Biliary Pancreatic surgery
1-1, Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan
022-717-7205
1st name | |
Middle name | |
Last name | Motoi Fuyuhiko |
Tohoku University Hospital
Hepato-Biliary Pancreatic surgery
1-1, Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan
022-717-7205
fmotoi@surg1.med.tohoku.ac.jp
Department of surgery, Tohoku University
None (self-funding)
Self funding
Japan
NO
2007 | Year | 12 | Month | 20 | Day |
Published
http://onlinelibrary.wiley.com/
The rate of clinically relevant POPF was significantly lower in the stented group than in the non-stented group: three of 47 (6 per cent) versus ten of 46 (22 per cent) (P = 0.040). Among patients with a dilated duct, rates of POPF were similar in both groups. Among patients with a non-dilated duct, clinically relevant POPF was significantly less common in the stented group than the non-stented group: two of 21 (10 per cent) versus eight of 20 (40 per cent) (P = 0.033).
Univariable analysis identified body mass index (BMI), pancreatic cancer, pancreatic texture, pancreatic duct size and duct stenting as risk factors related to clinically relevant POPF. Multivariable analysis taking these five factors into account identified high BMI (risk ratio (RR) 11.4; P = 0.009), non-dilated duct (RR 5.33; P = 0.047) and no stent (RR 10.4; P = 0.004) as significant risk factors.
Completed
2007 | Year | 11 | Month | 30 | Day |
2007 | Year | 12 | Month | 01 | Day |
2010 | Year | 07 | Month | 01 | Day |
2010 | Year | 08 | Month | 01 | Day |
2010 | Year | 09 | Month | 01 | Day |
2010 | Year | 10 | Month | 01 | Day |
2007 | Year | 12 | Month | 20 | Day |
2013 | Year | 08 | Month | 01 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001133